Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/30/09
End: 09/30/15
Due: 09/30/16
Phase: N/A
Priority: Normal
Start: 02/09/12
End: 02/20/19
Due: 02/20/20
Phase: N/A
Priority: Normal
Start: 02/21/17
End: 08/15/25
Due: 08/15/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | NCT00989586 | Beth Christian | user2@example.com | None | 2009-09-30 | 2015-09-30 | 2016-09-30 | - | - | 2025-07-14 |
| Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT01535924 | Beth Christian | user2@example.com | None | 2012-02-09 | 2019-02-20 | 2020-02-20 | - | - | 2025-07-14 |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT02992522 | Beth Christian | user2@example.com | None | 2017-02-21 | 2025-08-15 | 2026-08-15 | - | - | 2025-07-14 |